Home › Wilms Tumor › Illinois
Wilms Tumor clinical trials in Illinois
4 studies for Wilms Tumor are looking for participants at sites in Illinois.
Cities in Illinois
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 29, 2026 · NCT04616560Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Loyola University Medical Center, Maywood
- and 4 more
RecruitingPhase 2
Up to age 30 · All sexes · Updated Aug 25, 2026 · NCT04322318A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Ann & Robert H. Lurie Children'S Hospital of Chicag, Chicago
RecruitingPhase 2
12 Months · All sexes · Updated May 6, 2026 · NCT05985161From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.